ArticleACR open rheumatology2022

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome.

Sophanit Pepple et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.